Triple-Threat attack on blood cancer shows promise
Disease control
Ongoing
This study is testing a combination of three different drugs (obinutuzumab, ibrutinib, and venetoclax) to treat chronic lymphocytic leukemia (CLL). It aims to find the safest dose and see how well the combination works for patients whose cancer has returned, is resistant to treat…
Phase: PHASE1, PHASE2 • Sponsor: Kerry Rogers • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC